A phase 2 clinical trial published in The Lancet Gastroenterology & Hepatology found that dupilumab significantly improved symptoms and biological markers in patients with eosinophilic gastritis, a rare stomach disease with no approved treatments. The DEGAS study involved 41 patients across 11 U.S. centers.
Phase 3 trial results show amlitelimab met primary endpoints in two monotherapy studies for moderate-to-severe atopic dermatitis, with combination therapy demonstrating the strongest efficacy. The investigational OX40L-targeting antibody showed comparable efficacy between every-4-week and every-12-week dosing intervals. Safety data revealed two cases of Kaposi sarcoma in patients with known risk factors among 4,630 exposed patients.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
